아이슬란드 -
아이슬란드어 -
LYFJASTOFNUN (Icelandic Medicines Agency)
postafen tafla 25 mg
campuspharma ab - meclozinum hýdróklóríð - tafla - 25 mg
아이슬란드 -
아이슬란드어 -
LYFJASTOFNUN (Icelandic Medicines Agency)
bisbetol filmuhúðuð tafla 10 mg
williams & halls ehf. - bisoprololum fúmarat - filmuhúðuð tafla - 10 mg
아이슬란드 -
아이슬란드어 -
LYFJASTOFNUN (Icelandic Medicines Agency)
bisbetol filmuhúðuð tafla 5 mg
williams & halls ehf. - bisoprololum fúmarat - filmuhúðuð tafla - 5 mg
아이슬란드 -
아이슬란드어 -
LYFJASTOFNUN (Icelandic Medicines Agency)
sotalol viatris (sotalol mylan) tafla 40 mg
viatris limited - sotalolum hýdróklóríð - tafla - 40 mg
아이슬란드 -
아이슬란드어 -
LYFJASTOFNUN (Icelandic Medicines Agency)
sotalol viatris (sotalol mylan) tafla 80 mg
viatris limited - sotalolum hýdróklóríð - tafla - 80 mg
아이슬란드 -
아이슬란드어 -
LYFJASTOFNUN (Icelandic Medicines Agency)
metoprolol alvogen (metoprolin) tafla 100 mg
alvogen ehf. - metoprololum tartrat - tafla - 100 mg
아이슬란드 -
아이슬란드어 -
LYFJASTOFNUN (Icelandic Medicines Agency)
metoprolol alvogen (metoprolin) tafla 50 mg
alvogen ehf. - metoprololum tartrat - tafla - 50 mg
유럽 연합 -
아이슬란드어 -
EMA (European Medicines Agency)
braftovi
pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - Æxlishemjandi lyf - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.
아이슬란드 -
아이슬란드어 -
LYFJASTOFNUN (Icelandic Medicines Agency)
túfen saft 13,33 mg/ml
laboratoria qualiphar - guaifenesinum inn - saft - 13,33 mg/ml
아이슬란드 -
아이슬란드어 -
LYFJASTOFNUN (Icelandic Medicines Agency)
ritalin tafla 10 mg
infectopharm arzneimittel und consilium gmbh* - methylphenidatum hýdróklóríð - tafla - 10 mg